赫赛莱恩美曲妥珠单抗(Ado-trastuzumab emtansine)适应症恩美曲妥珠单抗(Ado-trastuzumabemtansine)在国内上市的商品名称为赫赛莱。恩美曲妥珠单抗是一种注射液,用于治疗HER2阳性转移性乳腺...2023-11-21 10:49:42 标签: 帕妥珠曲妥珠单抗注射液(皮下注射)(pertuzumab, trastuzumab, and hyaluronidase-zzxf)-Phesgo trastu...
恩美曲妥珠单抗: 一种HER2拮抗剂、ADCC药物,由Genentech, Inc. (Genentech, Inc.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: HER2拮抗剂(受体蛋白酪氨酸激酶 erbB-2拮抗剂),ADCC(抗体依赖的细胞毒作用),治疗领域: 肿瘤,皮肤和肌肉骨骼疾病,消化系统疾
ado‐trastuzumab emtansinetreatmentSummary Breast cancer is one of the commonest causes of death from a cancer in women. Human epidermal growth factor receptor 2 overexpression, found in 20–30% of breast cancer patients is associated with aggressive tumour behavior, and poorer prognosis. Tras...
ado-trastuzumab emtansinetreatmentRuhe ChowdhuryRichard Dimbleby Laboratory of Cancer Research, New Hunt House, Pilgrimage St, London SE1 1UL, UKPaul EllisGuys and St Thomas' NHS Trust, Guys Hospital, Great Maze Pond, London, SE1 9RT, UK
恩美曲妥珠单抗(Ado-trastuzumab emtansine)在技术上被称为HER2靶向抗体-药物缀合物,由两种抗癌药物组成,一种HER2靶向药物治疗(曲妥珠单抗trastuzumab)和一种化疗药物(emtansineDM1)。恩美曲妥珠单抗发现并附着在HER2+细胞外部的受体上。在这里,它通过阻止细胞生长和增强免疫系统杀死癌细胞的效果来发挥作用。恩美曲妥珠单抗也...
On February 22, 2013, the FDA licensed ado-trastuzumab emtansine (Kadcyla; Genentech, Inc.) for use as a single agent for the treatment of patients with hu... L Amiri-Kordestani,GM Blumenthal,QC Xu,... - 《Clinical Cancer Research》 被引量: 101发表: 2014年 Ado-trastuzumab emtansine (...
Trastuzumab emtansine | 曲妥珠单抗-美坦新偶联物 中文名:曲妥珠单抗-美坦新偶联物 CAS:1018448-65-1 品牌:MedChemExpress (MCE) 存储条件:Please store the product under the recommended conditions in th…
A Moderate Drug Interaction exists between ado-trastuzumab emtansine and tremelimumab. View detailed information regarding this drug interaction.
8月29日,FDA正式授予日本第一三共制药乳腺癌新药DS-8201 突破性疗法认定,该药物是一种ADC药物(抗体偶联药物),用于治疗既往接受曲妥单抗、帕妥珠单抗以及曲妥珠单抗抗体-药物偶联物(ado-trastuzumab emtansine)治疗后出现病情恶化的HER2阳性,局部晚期或者转移性乳腺癌患者。截止目前为止,尚未有任何一款药物获批用于经HER2...
肺癌的NCCN指南中针对ERBB2突变肺癌推荐ado-trastuzumab emtansine (T-DM1),证据级别为2A。另外指南明确指出ERBB2突变的肺腺癌患者并不合适曲妥珠单抗trastuzumab或者阿法替尼afatinib单药治疗,因为这两个药物先…